6533b873fe1ef96bd12d49e5

RESEARCH PRODUCT

IL-17 Inhibition in Spondyloarthritis Associates with Subclinical Gut Microbiome Perturbations and a Distinctive IL-25-Driven Intestinal Inflammation

Julia ManassonDavid S WallachGiuliana GugginoMatthew StapyltonMichelle H BadriGary SolomonSoumya M ReddyRoxana CorasAlexander A AksenovDrew R JonesParvathy V GirijaAndrea L NeimannAdriana HeguyLeopoldo N SegalPieter C DorresteinRichard BonneauMonica GumaFrancesco CicciaCarles UbedaJose C ClementeJose U Scher

subject

Settore MED/16 - ReumatologiaIL-17 inhibitorPsoriatic arthritiSpondyloarthritisMicrobiomeCandida

description

To characterize the ecological effects of biologic therapies on the gut bacterial and fungal microbiome of psoriatic arthritis (PsA)/spondyloarthritis (SpA) patients.

yearjournalcountryeditionlanguage
2020-01-01
10.1002/art.41169http://hdl.handle.net/11591/422629